Gilead's chief executive calls lenacapavir a once in a decade medicine. The HIV treatment could push Gilead stock further up ...

Addressing stigma, inequity, and access to HIV innovations remains critical to progress in the global HIV response, says IAS ...

Morgan Stanley has upgraded Gilead Sciences (GILD) to overweight from equal weight, citing the company's HIV drug lenacapavir. Read more here.

Promising new drugs to prevent and treat HIV have the potential to transform the response to the disease. But getting these ...

Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV ...

Research is a long-term endeavor requiring patience and foresight. Utah already ranks first in innovation, as previously ...

Investing.com -- Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP ...

The firm highlighted that Gilead's shares have seen a rise due to positive developments in its pipeline, particularly for Lenacapavir in HIV prevention and anito-cel in multiple myeloma.

The firm highlighted that Gilead's shares have seen a rise due to positive developments in its pipeline, particularly for Lenacapavir in HIV prevention and anito-cel in multiple myeloma. Gilead's ...

We have recently seen impressive results from the Purpose 1 and 2 studies, which evaluated the efficacy of [the drug] lenacapavir for prevention of HIV. In the Purpose 1 study, conducted among ...